The Sound of Evolution
Nintedanib
Mechanism of action:
Nintedanib is a multi-target tyrosine kinase inhibitor and an indolinone derivative. Nintedanib inhibits the tyrosine kinase ATP-binding sites of receptors such as PDGFR-α/PDGFR-β, FGFR 1/2/3, and VEGFR 1/2/3, thereby preventing their activation. This reduces tissue fibrosis and also suppresses angiogenesis, tumor proliferation, and metastatic potential within the tumor microenvironment.
Reference(s):
1. Keating GM et al. (2015). Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis. Drugs.
2. Hilberg F et al. (2008). BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res.
3. Mazzei ME et al. (2015). Nintedanib in the treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis.